Oneness Biotech Co., Ltd. (TPEX:4743)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
58.20
-0.10 (-0.17%)
At close: Feb 11, 2026
Market Cap27.89B -25.5%
Revenue (ttm)117.33M +4.6%
Net Income-1.40B
EPS-2.93
Shares Out478.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,912,543
Average Volume3,664,709
Open58.50
Previous Close58.30
Day's Range57.60 - 58.70
52-Week Range51.40 - 86.40
Beta0.90
RSI32.84
Earnings DateMar 6, 2026

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 4743
Full Company Profile

Financial Performance

In 2024, Oneness Biotech's revenue was 117.93 million, an increase of 35.89% compared to the previous year's 86.78 million. Losses were -1.17 billion, -11.25% less than in 2023.

Financial Statements